Breaking News on Supplements, Health & Nutrition - Europe US edition | APAC edition

Trends > Probiotics

EFSA beats off more Lactobacillus probiotic claims

By Shane Starling , 08-Aug-2012
Last updated on 19-Aug-2012 at 11:08 GMT2012-08-19T11:08:53Z

Lactobacillus gasseri
Lactobacillus gasseri

The most researched group of probiotic strains – Lactobacillus – has been delivered yet another blow by the EU’s central science agency, which rejected digestive and vaginal health claims for nine individual strains.

The rejected strains submitted to the European Food Safety Authority (EFSA) under article 13.1 of the EU nutrition and health claims regulation (NHCR) were:

  • Lactobacillus crispatus BCCM/LMG P-17631 (ID1030, 2950)
  • Lactobacillus gasseri BCCM/LMG P-17632 (ID 2956)
  • Lactobacillus gasseri BCCM/LMG P-18137 (ID 2957, 2958)
  • Lactobacillus paracasei CNCM I-1687 (ID 2960, 2961)
  • Lactobacillus paracasei CNCM I-1688 (ID 2962, 2963)
  • Lactobacillus plantarum BCCM/LMG P-17630 (ID 2966, 2967)
  • Lactobacillus salivarius CNCM I-1794 (ID 2970, 2971)
  • A blend of Bifidobacterium animalis ssp. lactis Bf-6 and Lactobacillus johnsonii La-1 (ACD-1)(CLbA22) (ID 4231)

Perhaps most intriguingly, a claim that some of the above probiotic strains (2960, 2962, 2971) could increase IL-10 production and/or enhance the activity of natural killer cells was turned down primarily because it was not deemed a beneficial effect.

“The Panel notes that increasing IL-10 production and/or enhancing the activity of natural killer cells is not a beneficial physiological effect per se, but needs to be linked to a beneficial physiological or clinical outcome,” said EFSA’s Panel on Dietetic Products, Nutrition and Allergies (NDA).

That hadn’t been done, so the claim was rejected.

For many of the submitted strains’ ability to reduce gastro-intestinal discomfort, the NDA said there were no intervention trials, “from which conclusions could be drawn for the scientific substantiation of the claim.”

For decreases in potentially pathogenic gastro-intestinal microorganisms the result was the same: No reliable intervention studies for the selected strains.

Improved lactose digestion for individuals with lactose maldigestion was similarly rejected.

‘Intestinal flora/digestive health’ was considered too general and non-specific a claim to be permissible under the NHCR.

Defence against vaginal pathogens was not backed by human intervention studies.

The NDA opinion can be found here.

Related products

Live Supplier Webinars

Polyphenols tipped to become the way to innovate in Sports Nutrition
Alpha & Omega in Sports Nutrition – Using Omega 3’s and A-GPC to improve performance and recovery.
KD Pharma
Orally bioavailable standardized botanical derivatives in sport nutrition: special focus on recovery in post-intense physical activities
Collagen in motion: move freely and keep your injuries in check
Leading manufacturer of gelatine and collagen peptides
Life’s too short for slow proteins. Whey proteins hydrolysates: Fast delivery for enhanced performance
Arla Foods Ingredients
What it Takes to Compete and Win in Today’s Sports Nutrition Market
Sports Nutrition Snapshot: Key regional drivers and delivery format innovations
William Reed Business Media
Gutsy performance: How can microbiome modulation help athletes and weekend warriors
William Reed Business Media
Pushing the boundaries: Where’s the line between ‘cutting edge nutrition’ and doping
William Reed Business Media

On demand Supplier Webinars

High-amylose maize starch may reduce the risk of type 2 diabetes: what does this qualified health claim mean?
Balancing Innovation and Risk in Sports Nutrition Ingredients
Explaining bio-hacking: is there a marketing opportunity for food companies?
William Reed Business Media
Personalized Nutrition – how an industry can take part in shaping the future of Nutrition
BASF Nutrition & Health
Find out Nutritional and ingredient lifecycle solutions and strategies!
Is the time rIpe for I-nutrition?
William Reed Business Media
The Advantage of Outsourcing Fermentation-based Manufacturing Processes
Evonik Health Care
All supplier webinars